AAPL343.20-0.26 (-0.08%) ▼|ABBV283.13-2.29 (-0.80%) ▼|ABT104.06-0.83 (-0.79%) ▼|ACN236.90+7.22 (+3.14%) ▲|ADBE247.09+1.89 (+0.77%) ▲|AMAT413.11+3.82 (+0.93%) ▲|AMD538.05+9.30 (+1.76%) ▲|AMGN424.94-7.55 (-1.75%) ▼|AMT183.05-2.22 (-1.20%) ▼|AMZN262.45+12.45 (+4.98%) ▲|AVGO334.59+5.84 (+1.78%) ▲|AXP316.37+2.78 (+0.88%) ▲|BA191.51+1.30 (+0.68%) ▲|BAC50.39-0.84 (-1.64%) ▼|BKNG162.60-0.85 (-0.52%) ▼|BLK1,124.83-9.56 (-0.84%) ▼|BMY58.84-0.91 (-1.52%) ▼|BNY142.41-0.89 (-0.62%) ▼|BRK-B532.47+0.45 (+0.08%) ▲|C121.72-2.54 (-2.04%) ▼|CAT725.77-4.99 (-0.68%) ▼|CL93.40-0.71 (-0.75%) ▼|CMCSA21.90+0.00 (+0.00%) ▲|COF199.86-1.88 (-0.93%) ▼|COP145.21-1.30 (-0.89%) ▼|COST995.53+6.42 (+0.65%) ▲|CRM242.46+1.76 (+0.73%) ▲|CSCO106.50-0.89 (-0.83%) ▼|CVS92.68+0.32 (+0.34%) ▲|CVX224.48-0.51 (-0.23%) ▼|DE627.30-14.56 (-2.27%) ▼|DHR224.39-4.65 (-2.03%) ▼|DIS109.58-1.01 (-0.91%) ▼|DUK119.26-2.21 (-1.82%) ▼|EMR160.52-0.95 (-0.59%) ▼|FDX293.81+0.26 (+0.09%) ▲|GD341.40-2.83 (-0.82%) ▼|GE311.34-2.49 (-0.79%) ▼|GEV908.35-12.85 (-1.39%) ▼|GILD153.07-3.12 (-2.00%) ▼|GM82.72-1.24 (-1.48%) ▼|GOOG340.16+3.25 (+0.96%) ▲|GOOGL344.18+3.59 (+1.05%) ▲|GS875.79-5.47 (-0.62%) ▼|HD309.99+0.36 (+0.12%) ▲|HON209.98-1.43 (-0.68%) ▼|IBM236.36+4.22 (+1.82%) ▲|INTC92.03+2.18 (+2.43%) ▲|INTU325.62+0.47 (+0.14%) ▲|ISRG433.18+6.48 (+1.52%) ▲|JNJ253.96-1.60 (-0.63%) ▼|JPM333.63-6.09 (-1.79%) ▼|KO93.44-0.47 (-0.50%) ▼|LIN503.44+5.01 (+1.01%) ▲|LLY1,240.40-16.63 (-1.32%) ▼|LMT548.45-3.64 (-0.66%) ▼|LOW195.90-1.48 (-0.75%) ▼|LRCX272.20+8.26 (+3.13%) ▲|MA616.27-1.15 (-0.19%) ▼|MCD242.63-0.34 (-0.14%) ▼|MDLZ63.34-0.57 (-0.89%) ▼|MDT92.74-2.01 (-2.12%) ▼|META705.44-3.89 (-0.55%) ▼|MMM162.10-2.65 (-1.61%) ▼|MO74.07-1.05 (-1.39%) ▼|MRK143.67-2.28 (-1.56%) ▼|MS178.49-2.08 (-1.15%) ▼|MSFT533.52+4.47 (+0.84%) ▲|MU904.90+26.06 (+2.97%) ▲|NEE78.18-1.62 (-2.03%) ▼|NFLX69.85-0.68 (-0.96%) ▼|NKE37.22+0.09 (+0.24%) ▲|NOW145.35+3.38 (+2.38%) ▲|NVDA217.09+2.96 (+1.38%) ▲|ORCL129.63+1.40 (+1.09%) ▲|PEP133.57+2.08 (+1.58%) ▲|PFE29.43-0.15 (-0.51%) ▼|PG157.71-1.64 (-1.03%) ▼|PLTR194.15+8.12 (+4.36%) ▲|PM200.98-4.22 (-2.06%) ▼|QCOM173.53+1.42 (+0.83%) ▲|RTX192.11-1.81 (-0.93%) ▼|SBUX97.87+0.35 (+0.36%) ▲|SCHW89.58-2.38 (-2.59%) ▼|SO89.27-1.91 (-2.09%) ▼|SPG202.49-2.95 (-1.44%) ▼|T23.20-0.24 (-1.02%) ▼|TMO679.28-10.72 (-1.55%) ▼|TMUS156.09-3.01 (-1.89%) ▼|TSLA368.06+13.34 (+3.76%) ▲|TXN276.15-0.33 (-0.12%) ▼|UBER69.96-0.39 (-0.55%) ▼|UNH406.88+5.45 (+1.36%) ▲|UNP287.01-2.03 (-0.70%) ▼|UPS97.46-0.02 (-0.02%) ▼|USB57.85-0.88 (-1.50%) ▼|V402.92+0.31 (+0.08%) ▲|VZ44.15-0.64 (-1.43%) ▼|WFC81.80-2.07 (-2.47%) ▼|WMT118.70-0.11 (-0.09%) ▼|XOM178.28-0.70 (-0.39%) ▼|AAPL343.20-0.26 (-0.08%) ▼|ABBV283.13-2.29 (-0.80%) ▼|ABT104.06-0.83 (-0.79%) ▼|ACN236.90+7.22 (+3.14%) ▲|ADBE247.09+1.89 (+0.77%) ▲|AMAT413.11+3.82 (+0.93%) ▲|AMD538.05+9.30 (+1.76%) ▲|AMGN424.94-7.55 (-1.75%) ▼|AMT183.05-2.22 (-1.20%) ▼|AMZN262.45+12.45 (+4.98%) ▲|AVGO334.59+5.84 (+1.78%) ▲|AXP316.37+2.78 (+0.88%) ▲|BA191.51+1.30 (+0.68%) ▲|BAC50.39-0.84 (-1.64%) ▼|BKNG162.60-0.85 (-0.52%) ▼|BLK1,124.83-9.56 (-0.84%) ▼|BMY58.84-0.91 (-1.52%) ▼|BNY142.41-0.89 (-0.62%) ▼|BRK-B532.47+0.45 (+0.08%) ▲|C121.72-2.54 (-2.04%) ▼|CAT725.77-4.99 (-0.68%) ▼|CL93.40-0.71 (-0.75%) ▼|CMCSA21.90+0.00 (+0.00%) ▲|COF199.86-1.88 (-0.93%) ▼|COP145.21-1.30 (-0.89%) ▼|COST995.53+6.42 (+0.65%) ▲|CRM242.46+1.76 (+0.73%) ▲|CSCO106.50-0.89 (-0.83%) ▼|CVS92.68+0.32 (+0.34%) ▲|CVX224.48-0.51 (-0.23%) ▼|DE627.30-14.56 (-2.27%) ▼|DHR224.39-4.65 (-2.03%) ▼|DIS109.58-1.01 (-0.91%) ▼|DUK119.26-2.21 (-1.82%) ▼|EMR160.52-0.95 (-0.59%) ▼|FDX293.81+0.26 (+0.09%) ▲|GD341.40-2.83 (-0.82%) ▼|GE311.34-2.49 (-0.79%) ▼|GEV908.35-12.85 (-1.39%) ▼|GILD153.07-3.12 (-2.00%) ▼|GM82.72-1.24 (-1.48%) ▼|GOOG340.16+3.25 (+0.96%) ▲|GOOGL344.18+3.59 (+1.05%) ▲|GS875.79-5.47 (-0.62%) ▼|HD309.99+0.36 (+0.12%) ▲|HON209.98-1.43 (-0.68%) ▼|IBM236.36+4.22 (+1.82%) ▲|INTC92.03+2.18 (+2.43%) ▲|INTU325.62+0.47 (+0.14%) ▲|ISRG433.18+6.48 (+1.52%) ▲|JNJ253.96-1.60 (-0.63%) ▼|JPM333.63-6.09 (-1.79%) ▼|KO93.44-0.47 (-0.50%) ▼|LIN503.44+5.01 (+1.01%) ▲|LLY1,240.40-16.63 (-1.32%) ▼|LMT548.45-3.64 (-0.66%) ▼|LOW195.90-1.48 (-0.75%) ▼|LRCX272.20+8.26 (+3.13%) ▲|MA616.27-1.15 (-0.19%) ▼|MCD242.63-0.34 (-0.14%) ▼|MDLZ63.34-0.57 (-0.89%) ▼|MDT92.74-2.01 (-2.12%) ▼|META705.44-3.89 (-0.55%) ▼|MMM162.10-2.65 (-1.61%) ▼|MO74.07-1.05 (-1.39%) ▼|MRK143.67-2.28 (-1.56%) ▼|MS178.49-2.08 (-1.15%) ▼|MSFT533.52+4.47 (+0.84%) ▲|MU904.90+26.06 (+2.97%) ▲|NEE78.18-1.62 (-2.03%) ▼|NFLX69.85-0.68 (-0.96%) ▼|NKE37.22+0.09 (+0.24%) ▲|NOW145.35+3.38 (+2.38%) ▲|NVDA217.09+2.96 (+1.38%) ▲|ORCL129.63+1.40 (+1.09%) ▲|PEP133.57+2.08 (+1.58%) ▲|PFE29.43-0.15 (-0.51%) ▼|PG157.71-1.64 (-1.03%) ▼|PLTR194.15+8.12 (+4.36%) ▲|PM200.98-4.22 (-2.06%) ▼|QCOM173.53+1.42 (+0.83%) ▲|RTX192.11-1.81 (-0.93%) ▼|SBUX97.87+0.35 (+0.36%) ▲|SCHW89.58-2.38 (-2.59%) ▼|SO89.27-1.91 (-2.09%) ▼|SPG202.49-2.95 (-1.44%) ▼|T23.20-0.24 (-1.02%) ▼|TMO679.28-10.72 (-1.55%) ▼|TMUS156.09-3.01 (-1.89%) ▼|TSLA368.06+13.34 (+3.76%) ▲|TXN276.15-0.33 (-0.12%) ▼|UBER69.96-0.39 (-0.55%) ▼|UNH406.88+5.45 (+1.36%) ▲|UNP287.01-2.03 (-0.70%) ▼|UPS97.46-0.02 (-0.02%) ▼|USB57.85-0.88 (-1.50%) ▼|V402.92+0.31 (+0.08%) ▲|VZ44.15-0.64 (-1.43%) ▼|WFC81.80-2.07 (-2.47%) ▼|WMT118.70-0.11 (-0.09%) ▼|XOM178.28-0.70 (-0.39%) ▼|
17.7 C
New York
Monday, October 19, 2026

Tag: cellular

newssourceFORcompanycontentinformation1releasesmarket

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Millicom (Tigo) Reaches Strategic Agreement with EPM to facilitate Merger Process with ColTel

Millicom (Tigo) Reaches Strategic Agreement with EPM to facilitate Merger Process with ColTel

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in...

NativePath Liposomal Vitamin C: Urgent 2025 Consumer Warning on Why Most Vitamin C Pills May Fail — And the 3-in-1 Formula Positioned for Better...

Public interest in vitamin C has surged in 2025 as consumers search for cleaner, more effective options beyond standard pills. Across TikTok, Reddit, and wellness forums, questions are rising about ingredient sources, absorption rates, and the difference between synthetic ascorbic acid and real, whole-food vitamin C. NativePath Liposomal Vitamin C is positioned within this growing trend, featuring an amla-based 3-in-1 formula designed for nutrient integrity and advanced delivery. It reflects a broader shift toward transparency, clean sourcing, and solutions that align with evolving health and wellness priorities. 
Public interest in vitamin C has surged in 2025 as consumers search for cleaner, more effective options beyond standard pills. Across TikTok, Reddit, and wellness forums, questions are rising about ingredient sources, absorption rates, and the difference between synthetic ascorbic acid and real, whole-food vitamin C. NativePath Liposomal Vitamin C is positioned within this growing trend, featuring an amla-based 3-in-1 formula designed for nutrient integrity and advanced delivery. It reflects a broader shift toward transparency, clean sourcing, and solutions that align with evolving health and wellness priorities.

Vertigenics – The Natural Vertigo Breakthrough Driving 2025 Interest in Balance and Brain Support Formulas

Public Interest in Natural Vertigo Support and Ingredient-First Balance Formulas Continues to Rise in 2025 
Public Interest in Natural Vertigo Support and Ingredient-First Balance Formulas Continues to Rise in 2025

Vitanergy Health US Inc. Launches Three New Dietary Supplements to Support Women’s Daily Wellness

Now available on Amazon, Walmart Marketplace, Flaire.com, and Vitanergy.com—Formulated with high-quality ingredients and made in the USA. LAS VEGAS, Aug. 13, 2025 /PRNewswire/ -- Vitanergy...

AlphaCur Gains Momentum in 2025 as a Leading Formula for Neuropathy Nerve Health Support

AlphaCur Introduces Ingredient-First Nerve Health Formula as Interest in Neuropathy Support and Long-Term Wellness Grows in 2025 
AlphaCur Introduces Ingredient-First Nerve Health Formula as Interest in Neuropathy Support and Long-Term Wellness Grows in 2025

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead investigational therapy, CELZ-201-DDT, for the treatment of degenerative disc disease (DDD), a major cause of chronic lower back pain and disability.

MedTech Manufacturer Juvent Joins the Inc. 5000 List of America’s Fastest-Growing Private Companies

Juvent joins the 2025 Inc. 5000, ranking #757 with 552% growth over 3 years, for its Micro-Impact Platform, which improves mobility, pain, and wellness.

5 Pew-Stewart Scholars Selected to Pursue Pioneering Cancer Research

PHILADELPHIA, Aug. 12, 2025 /PRNewswire/ -- The Pew Charitable Trusts and the Alexander and Margaret Stewart Trust announced today the 2025 class of the...

VEON’s Kyivstar Delivers First Messages via Starlink in Direct to Cell Satellite Connectivity Test in Ukraine

Dubai and Kyiv, August 12, 2025 – VEON Ltd. (Nasdaq: VEON), a global digital operator, today announces that Kyivstar, its digital operator in Ukraine, has successfully conducted a test of satellite and terrestrial network integration using Starlink Direct to Cell technology. This is the first field test of of Starlink Direct to Cell in eastern Europe. 

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Perimeter Announces Preliminary Unaudited Revenues for the 2025 Second Quarter; Reduces Operating Costs by ~30% as Company Focuses on Commercial Sales Pipeline and Growth...

– Webcasted Q2-2025 conference call scheduled for August 26th at 5:00 PM EDT – TORONTO and DALLAS, Aug. 11, 2025 /PRNewswire/ - Perimeter Medical Imaging AI,...

Perimeter Announces Preliminary Unaudited Revenues for the 2025 Second Quarter; Reduces Operating Costs by ~30% as Company Focuses on Commercial Sales Pipeline and Growth...

– Webcasted Q2-2025 conference call scheduled for August 26th at 5:00 PM EDT – TORONTO and DALLAS, Aug. 11, 2025 /CNW/ - Perimeter Medical Imaging AI,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCellular

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers